Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 254

Results For "EU"

5723 News Found

Lupin receives USFDA approval for Bumetanide Injection
Drug Approval | September 19, 2024

Lupin receives USFDA approval for Bumetanide Injection

Bumetanide Injection USP (RLD Bumex) had estimated annual sales of USD 20 million in the U.S.


Fasenra approved in the US for eosinophilic granulomatosis with polyangiitis
Drug Approval | September 19, 2024

Fasenra approved in the US for eosinophilic granulomatosis with polyangiitis

New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids


Suven Life Sciences announces positive topline results from Phase-2 PoC signal detection open label study of Ropanicant
News | September 18, 2024

Suven Life Sciences announces positive topline results from Phase-2 PoC signal detection open label study of Ropanicant

The primary objective was to evaluate safety and tolerability of Ropanicant in patients with MDD


Lupin inks licensing agreement with Takeda to commercialize Vonoprazan
News | September 18, 2024

Lupin inks licensing agreement with Takeda to commercialize Vonoprazan

Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India


Alembic appoints Sudhakar Pandiyan as Head - Technical Operations
People | September 17, 2024

Alembic appoints Sudhakar Pandiyan as Head - Technical Operations

He has been associated with Caplin Steriles Ltd., Mylan Laboratories Ltd., Caplin Point Laboratories Ltd., Strides Arcolab Ltd. and Novartis Vaccines and Diagnostics


Piramal Pharma's GHG Commitment Validated and Approved by SBTi
Sustainability | September 17, 2024

Piramal Pharma's GHG Commitment Validated and Approved by SBTi

This validation aligns with Piramal Pharma's core purpose of 'Doing Well and Doing Good,'


Wacker collaborates with MinervaX for prophylactic vaccine targeting Group B streptococcus
News | September 17, 2024

Wacker collaborates with MinervaX for prophylactic vaccine targeting Group B streptococcus

Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate


Wockhardt wins “BIRAC Innovator Award 2024”
News | September 16, 2024

Wockhardt wins “BIRAC Innovator Award 2024”

The award is for development of Nafithromycin, which is the first ever multi-drug resistant pathogen active respiratory antibiotic for the treatment of Community-Acquired Bacterial Pneumonia


10 year data for Merck’s Keytruda demonstrates sustained overall survival benefit versus Ipilimumab in advanced melanoma
Clinical Trials | September 16, 2024

10 year data for Merck’s Keytruda demonstrates sustained overall survival benefit versus Ipilimumab in advanced melanoma

At 10 years, more than one-third (34.0%) of patients with advanced melanoma were alive after treatment with KEYTRUDA, compared to 23.6% of patients treated with ipilimumab